WO2020063370A3 - 免疫组合物及其制备方法与应用 - Google Patents

免疫组合物及其制备方法与应用 Download PDF

Info

Publication number
WO2020063370A3
WO2020063370A3 PCT/CN2019/105716 CN2019105716W WO2020063370A3 WO 2020063370 A3 WO2020063370 A3 WO 2020063370A3 CN 2019105716 W CN2019105716 W CN 2019105716W WO 2020063370 A3 WO2020063370 A3 WO 2020063370A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
method therefor
immune composition
application
vzv
Prior art date
Application number
PCT/CN2019/105716
Other languages
English (en)
French (fr)
Other versions
WO2020063370A2 (zh
WO2020063370A4 (zh
Inventor
慕婷
赵萍
徐龙
肖杨
朱利安·琼·菲利普
吴月
谢亮
陈雪婷
刘奇
谢铎源
庄再成
克莱因·米歇尔
杜林森
吴克
Original Assignee
武汉博沃生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 武汉博沃生物科技有限公司 filed Critical 武汉博沃生物科技有限公司
Priority to AU2019349036A priority Critical patent/AU2019349036A1/en
Priority to EP19866309.8A priority patent/EP3868399A4/en
Priority to CN201980063806.6A priority patent/CN113164586B/zh
Priority to CA3114658A priority patent/CA3114658A1/en
Publication of WO2020063370A2 publication Critical patent/WO2020063370A2/zh
Publication of WO2020063370A3 publication Critical patent/WO2020063370A3/zh
Publication of WO2020063370A4 publication Critical patent/WO2020063370A4/zh
Priority to US17/216,619 priority patent/US20210290759A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种免疫组合物及其制备方法与应用。本发明通过原核表达体系或重组腺病毒体系高效表达VZV包膜gE糖蛋白及其gE鞭毛素融合蛋白。将制得的重组gE蛋白、gE鞭毛素融合蛋白及重组腺病毒载体或其组合物免疫小鼠后可刺激机体产生gE和VZV特异性抗体滴度及gE和VZV特异性的细胞免疫。
PCT/CN2019/105716 2018-09-27 2019-09-12 免疫组合物及其制备方法与应用 WO2020063370A2 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2019349036A AU2019349036A1 (en) 2018-09-27 2019-09-12 Immune composition, preparation method therefor, and application thereof
EP19866309.8A EP3868399A4 (en) 2018-09-27 2019-09-12 IMMUNE COMPOSITION, METHOD FOR PREPARATION AND ASSOCIATED APPLICATION
CN201980063806.6A CN113164586B (zh) 2018-09-27 2019-09-12 免疫组合物及其制备方法与应用
CA3114658A CA3114658A1 (en) 2018-09-27 2019-09-12 Immune composition, preparation method therefor and use thereof
US17/216,619 US20210290759A1 (en) 2018-09-27 2021-03-29 Immune composition, preparation method therefor, and application thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201811131501.8 2018-09-27
CN201811131501 2018-09-27
CN201910571839 2019-06-28
CN201910571839.3 2019-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/216,619 Continuation-In-Part US20210290759A1 (en) 2018-09-27 2021-03-29 Immune composition, preparation method therefor, and application thereof

Publications (3)

Publication Number Publication Date
WO2020063370A2 WO2020063370A2 (zh) 2020-04-02
WO2020063370A3 true WO2020063370A3 (zh) 2020-05-22
WO2020063370A4 WO2020063370A4 (zh) 2020-06-25

Family

ID=69953299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/105716 WO2020063370A2 (zh) 2018-09-27 2019-09-12 免疫组合物及其制备方法与应用

Country Status (6)

Country Link
US (1) US20210290759A1 (zh)
EP (1) EP3868399A4 (zh)
CN (1) CN113164586B (zh)
AU (1) AU2019349036A1 (zh)
CA (1) CA3114658A1 (zh)
WO (1) WO2020063370A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN110343722A (zh) * 2019-07-03 2019-10-18 上海大学 一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法
CN112552380B (zh) * 2020-12-10 2021-12-24 武汉博沃生物科技有限公司 一种SARS-CoV-2病毒的免疫原及其应用
TWI782542B (zh) * 2021-05-25 2022-11-01 國立屏東科技大學 一種鞭毛蛋白的重組蛋白及其用途
CN115819616A (zh) * 2021-07-28 2023-03-21 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
CN114163503B (zh) * 2021-12-15 2023-11-24 北京交通大学 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用
CN116350770A (zh) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2023179588A1 (zh) * 2022-03-21 2023-09-28 厦门大学 截短的水痘-带状疱疹病毒囊膜糖蛋白gE
US20240148861A1 (en) * 2022-11-08 2024-05-09 Vernagen, LLC Engineered varicella zoster virus shingles mrna vaccine
CN116023510B (zh) * 2022-12-01 2023-09-22 北京吉诺卫生物科技有限公司 双佐剂重组带状疱疹疫苗
CN117003894B (zh) * 2023-08-09 2024-04-16 成都新诺明生物科技有限公司 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189254A (zh) * 2005-03-03 2008-05-28 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2011063660A1 (zh) * 2009-11-27 2011-06-03 中国科学院武汉病毒研究所 优化的鞭毛素蛋白及其制备方法和应用
CN102203252A (zh) * 2008-06-25 2011-09-28 法国国家健康和医学研究所 基于鞭毛蛋白的新型免疫佐剂化合物及其用途
CN102816246A (zh) * 2012-09-04 2012-12-12 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
CN103861101A (zh) * 2014-03-12 2014-06-18 中国药科大学 一种幽门螺杆菌多表位疫苗的新型嵌合鞭毛蛋白佐剂
CN103945863A (zh) * 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
CN105906721A (zh) * 2016-06-21 2016-08-31 芜湖天明生物技术有限公司 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
CN107106705A (zh) * 2014-10-21 2017-08-29 锦玟生命科学（株） 用于预防和治疗带状疱疹的dna疫苗组合物，以及使用其激活针对vzv抗原的t细胞的方法
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
EP2670443A4 (en) * 2011-01-31 2015-10-14 Univ Pennsylvania NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USING SAME
CN102488898B (zh) * 2011-12-23 2014-06-04 中国科学院武汉病毒研究所 龋齿疫苗及制备方法
WO2016054696A1 (en) * 2014-10-09 2016-04-14 Lipotek Pty Ltd Chimeric proteins
JP6367783B2 (ja) * 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
WO2018124615A1 (ko) * 2016-12-26 2018-07-05 재단법인 목암생명과학연구소 대상포진 백신 조성물

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189254A (zh) * 2005-03-03 2008-05-28 葛兰素史密丝克莱恩生物有限公司 疫苗
CN102203252A (zh) * 2008-06-25 2011-09-28 法国国家健康和医学研究所 基于鞭毛蛋白的新型免疫佐剂化合物及其用途
WO2011063660A1 (zh) * 2009-11-27 2011-06-03 中国科学院武汉病毒研究所 优化的鞭毛素蛋白及其制备方法和应用
CN103945863A (zh) * 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
CN102816246A (zh) * 2012-09-04 2012-12-12 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
CN103861101A (zh) * 2014-03-12 2014-06-18 中国药科大学 一种幽门螺杆菌多表位疫苗的新型嵌合鞭毛蛋白佐剂
CN107106705A (zh) * 2014-10-21 2017-08-29 锦玟生命科学（株） 用于预防和治疗带状疱疹的dna疫苗组合物，以及使用其激活针对vzv抗原的t细胞的方法
CN105906721A (zh) * 2016-06-21 2016-08-31 芜湖天明生物技术有限公司 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用

Also Published As

Publication number Publication date
EP3868399A2 (en) 2021-08-25
WO2020063370A2 (zh) 2020-04-02
CN113164586A (zh) 2021-07-23
AU2019349036A8 (en) 2021-06-24
CA3114658A1 (en) 2020-04-02
WO2020063370A4 (zh) 2020-06-25
AU2019349036A1 (en) 2021-06-03
EP3868399A4 (en) 2022-07-20
US20210290759A1 (en) 2021-09-23
CN113164586B (zh) 2024-04-16

Similar Documents

Publication Publication Date Title
WO2020063370A3 (zh) 免疫组合物及其制备方法与应用
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2019011599A (es) Moleculas quimericas y usos de las mismas.
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MX2016008958A (es) Proteinas quimericas de factor viii y usos de estas.
WO2014139476A8 (zh) Rsv融合蛋白的表位以及识别其的抗体
DK1968632T3 (da) Forbedret influenzavaccine
EA035991B9 (ru) Новый полисахарид и его применения
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
WO2019126464A3 (en) Compositions and methods for treating hiv/aids with immunotherapy
BR112015022617A2 (pt) polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável
WO2015023891A3 (en) Factor viii-xten fusions and uses thereof
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2017132332A8 (en) Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
HRP20200285T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
PH12020552009A1 (en) Antigen variant of varicella zoster virus and use thereof
MX2011007307A (es) Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.
WO2019006401A3 (en) LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
WO2017142843A8 (en) Novel antigen for use in malaria vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19866309

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3114658

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019866309

Country of ref document: EP

Effective date: 20210428

ENP Entry into the national phase

Ref document number: 2019349036

Country of ref document: AU

Date of ref document: 20190912

Kind code of ref document: A